Syntara (SNT) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
23 Jun, 2026Opening remarks and agenda
Meeting opened by CFO and Company Secretary, with introductions of the board and explanation of the virtual format.
Notice of meeting and proposed resolutions taken as read, with voting and Q&A procedures outlined.
Specific resolutions to be voted on
Resolution one: Approval of the issue of shares under the second tranche of a placement announced in April 2026, with voting exclusions applied.
Resolution two: Ratification of the issue of shares under the first tranche placement from April 2026 to refresh the 15% capacity, with voting exclusions applied.
Q&A with stakeholders
Opportunity for questions provided after each resolution, but no questions were raised by shareholders or proxies.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Syntara
- FDA-backed late-stage trials and strong cash position set up major clinical catalysts in H2 2026.SNT
Q4 2026 TU - Phase II/2a trial of SNT-4728 targets neuroinflammation in iRBD, results due by June or 2026.SNT
Status update - FDA supports Phase 2b for amsulostat; cash runway extended after A$8m placement.SNT
Q3 2026 TU - FDA backs Phase 2b amsulostat trial; funding secured for key 2026 milestones.SNT
Investor update - Amsulostat shows promising efficacy in myelofibrosis, with funding secured for pivotal trials.SNT
Investor presentation - Net loss widened to $15.1M as revenue fell and cost reductions followed the MBU sale.SNT
H2 2024 - Reduced net loss, strong cash, and key clinical milestones as a pure-play drug developer.SNT
H2 2025 - 73% achieved TSS50 and 44% SVR25 with strong tolerability and ongoing development plans.SNT
Study Update - Phase 2 myelofibrosis trial fully recruited; A$5m raised; interim data due December 2024.SNT
Q1 2025 TU